Trial Profile
Comparison of the effects of combined rate and rhythm control treatment with Nebivolol and electric cardioversion to rate-control treatment with Nebivolol alone on clinical and echocardiographic parameters in patients with Left ventricular dysfunction induced tachycardia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Feb 2010
Price :
$35
*
At a glance
- Drugs Nebivolol (Primary)
- Indications Left ventricular dysfunction; Tachycardia
- Focus Registrational; Therapeutic Use
- Acronyms NEBICAR
- Sponsors Berlin Chemie
- 07 Apr 2008 New trial record.